Spero Therapeutics Inc

2HA

Company Profile

  • Business description

    Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

  • Contact

    675 Massachusetts Avenue
    14th Floor
    CambridgeMA02139
    USA

    T: +1 857 242-1600

    E: [email protected]

    https://www.sperotherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    25

Stocks News & Analysis

stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.
stocks

Investor Playbook: Can your portfolio handle what’s next?

Testing portfolio resilience in an uncertain market.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,194.709.80-0.11%
CAC 408,368.917.550.09%
DAX 4026,749.9521.93-0.08%
Dow JONES (US)52,347.5550.460.10%
FTSE 10010,902.5639.470.36%
HKSE23,802.30164.700.70%
NASDAQ25,136.27229.82-0.91%
Nikkei 22560,176.85965.50-1.58%
NZX 50 Index14,242.1368.450.48%
S&P 5007,561.6730.73-0.40%
S&P/ASX 2009,073.708.50-0.09%
SSE Composite Index3,601.0533.30-0.92%

Market Movers